Intravitreal ranibizumab maintained best corrected visual acuity and diminished central macular thickness in patients with choroidal neovascularization due to adult-onset foveomacular vitelliform dystrophy, according to a study.
The retrospective case series included 24 eyes that were treated with three monthly intravitreal injections of Lucentis (ranibizumab, Genentech).
Patients were followed for 12 months. Treatment was continued after the initial three monthly injections if necessary.
Twenty-one eyes lost fewer than three lines of visual acuity from baseline to final visit.
No significant change was found in BCVA from baseline to final visit; however, mean central macular thickness diminished significantly from baseline to final visit (327 µm vs. 260 µm, P = .001).